RxDoctor Payments Data

Linda Luong, MD

Family Medicine · Winchester, VANPI 1689647257

Payments from drug & device makers

$732in general payments, 2019–2025

Across 55 payments — averaging $13.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Novo Nordisk$143
  • AstraZeneca$89
  • Abbott$62
  • Lilly USA, LLC$55
  • Sanofi Pasteur Inc.$24
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)28$316
Novo Nordisk10$143
AstraZeneca6$89
Abbott3$62
Lilly USA, LLC3$55
Sanofi Pasteur Inc.2$24
Boehringer Ingelheim1$15
Amgen1$15
Pfizer1$14

How this compares

$732 in reported general payments places this provider in the 60th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$139,167
Medicare patients
305
Services billed
1,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$46,112
OzempicSemaglutide33$45,757
TrulicityDulaglutide32$45,269
RybelsusSemaglutide18$22,569
MounjaroTirzepatide20$19,095
EliquisApixaban15$18,756
Spiriva RespimatTiotropium Bromide24$15,988
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,079
Breo ElliptaFluticasone/Vilanterol12$5,835
Rosuvastatin Calcium126$2,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,376
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,283
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,975
Estradiol18$1,891
Famotidine107$1,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$143$68,32651 claims
Lilly USA, LLCTrulicity, Mounjaro$55$64,36452 claims
Boehringer IngelheimJardiance, Spiriva Respimat$15$62,10057 claims
PfizerEliquis$14$18,75615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →